Clinical trial
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic…
NCT00234494 · Christopher Sweeney, MBBS, Other · Completed
Key facts
| NCT number | NCT00234494 |
|---|---|
| Title | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer |
| Official title | A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75 |
| Lead sponsor | Christopher Sweeney, MBBS, Other |
| Collaborators | Genentech, Inc. Industry Eli Lilly and Company Walther Cancer Institute Hoosier Cancer Research Network |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | Cisplatin, Gemcitabine, Bevacizumab |
| Enrollment | 45 |
| Start date | Nov 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Oct 7, 2005 |
| Last update posted | Mar 14, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: